Monoclonal antibodies mimic natural proteins found in the body to specifically and effectively target abnormal cells. Dr Martin Kaiser explains how these are being developed to treat myeloma.
Dr Martin Kaiser explains how the genetics of myeloma play an important role in the development of myeloma, the importance of genetics in how different groups of patients respond to different treatments and how the role of genetics play an increasing role in developing new and effective myeloma treatments.
Proteasome inhibitor drugs are a class of drug used to treat myeloma and include bortezomib (Velcade®) as well as other drugs in clinical trial and development including carfilzomib (Kyprolis®) and ixazomib (Ninlaro®). Dr Charlotte Pawlyn explains how they work and why they are effective in treating myeloma.